Lineage Cell Therapeutics (LCTX) Corporate Presentation from NobleCon18Research, News and Market Data on Lineage Cell TherapeuticsNobleCon 18 Complete Rebroadcast
|
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
‌


Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌


1/29/2026
Transportation
VSE’s $2 Billion Investment in Precision Aviation Signals a New Era in the Aviation Aftermarket
VSE Corporation’s agreement to acquire Precision Aviation Group (PAG) for approximately $2.025 billion marks a transformational moment—not just for the company, but for the broader aviation aftermarket industry. The deal...
3 min read
‌


1/29/2026
Aerospace and Defense
Release – V2X and Amazon to Partner on Smart Warehousing and Global Logistics Automation
V2X, Inc. (NYSE: VVX) today announced a key strategic partnership with Amazon to deliver smart warehousing and automation technologies to the companies’ mutual U.S. Government customers to support a diverse...
3 min read
‌


1/29/2026
Media and Entertainment
Release – Federal Court Dismisses All of Remaining Claims Against SEGG Media
SEGG Media Corporation, formerly Lottery.com Inc., (NASDAQ: SEGG, LTRYW)(the “Company” or “SEGG Media”), the global sports, entertainment, and gaming group continues its transparent and material transformation as it announces today...
5 min read
‌


1/29/2026
Health
Release – UPDATE – Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA)...
6 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.